Drug interactions
Empagliflozin-linagliptin + Sotorasib
Severity: Minor
Empagliflozin-linagliptin and Sotorasib: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Sotorasib is a weak P-gp inducer or modulator that could in theory alter linagliptin exposure. The clinical effect is expected to be small, and the legacy direction is uncertain.
What this interaction means in plain words
Empagliflozin-linagliptin and Sotorasib have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Empagliflozin-linagliptin belongs to Endocrine; Sotorasib belongs to Oncology.
Why it happens
Possible modulation of P-glycoprotein transport of linagliptin; the mechanism is not firmly established.
What to do
No empirical dose adjustment is needed; monitor HbA1c and glucose values if the combination is started or stopped.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Empagliflozin-linagliptin and Sotorasib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Empagliflozin-linagliptin
Other interactions of Sotorasib
- Amobarbital + Sotorasib Major
- Apalutamide + Sotorasib Major
- Carbamazepine + Sotorasib Major
- Colchicine + Sotorasib Major
- Cyclosporin + Sotorasib Major
- Digoxin + Sotorasib Major
Frequently asked questions
Can I take Empagliflozin-linagliptin with Sotorasib?
MediHelp rates the interaction as minor. Empagliflozin-linagliptin and Sotorasib have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Sotorasib is a weak P-gp inducer or modulator that could in theory alter linagliptin exposure. The clinical effect is expected to be small, and the legacy direction is uncertain.
How serious is the interaction between Empagliflozin-linagliptin and Sotorasib?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: No empirical dose adjustment is needed; monitor HbA1c and glucose values if the combination is started or stopped.
What other medicines interact with Empagliflozin-linagliptin?
MediHelp also lists interactions of Empagliflozin-linagliptin with, for example, Fosphenytoin, Rifampin, Rifapentine. The full list is on the Empagliflozin-linagliptin page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
